Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 4,667 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Defibrotide for the Treatment of Severe COVID-19

NCT04652115
View directory record Official record
Conditions
Covid19
Interventions
Defibrotide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 31, 2026, 2:13 PM EDT
Terminated Phase 2 Interventional

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

NCT04053543
View directory record Official record
Conditions
PAH
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

NCT05274815
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Newport Beach, California • Newark, Delaware • Loxahatchee Groves, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

NCT01695343
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
KB001-A, Placebo Comparator
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
58
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT02492867
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel, FDG-PET, V/Q SPECT, Durvalumab
Radiation · Drug · Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Apnea, Bariatric Surgery Versus Continuous Positive Airway Pressure (CPAP) Trial

NCT01187771
View directory record Official record
Conditions
Obstructive Sleep Apnea, Obesity
Interventions
Laparoscopic Gastric Banding, Continuous Positive Airway Pressure
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 31, 2026, 2:13 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

NCT03425006
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Itacitinib, Pembrolizumab
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 3 Interventional Results available

Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)

NCT04402970
View directory record Official record
Conditions
SARS-CoV 2, ARDS
Interventions
Dornase Alfa Inhalation Solution
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Not applicable Interventional

CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment

NCT04431856
View directory record Official record
Conditions
Anxiety, Depression, Traumatic Stress Disorder
Interventions
Unified Protocol for COVID-19 Parenting Stress (UP-COVID), SHG
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

NCT00163501
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
41
States / cities
Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 31, 2026, 2:13 PM EDT
Terminated Phase 3 Interventional

Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

NCT04672564
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Carrimycin, Placebo
Drug
Lead sponsor
Shenyang Tonglian Group CO., Ltd
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT03132532
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Etoposide, Paclitaxel, Pemetrexed, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Results available

N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)

NCT04706416
View directory record Official record
Conditions
Coronavirus, Covid19
Interventions
N-acetyl glucosamine (NAG), Control
Dietary Supplement · Other
Lead sponsor
Quantinosis.ai LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

NCT00815919
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
bortezomib, Prednisone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 31, 2026, 2:13 PM EDT
Active, not recruiting Phase 2 Interventional

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

NCT03010436
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 2Phase 3 Interventional Results available

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00463567
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
Interventions
Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
2,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
221
States / cities
Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 31, 2026, 2:13 PM EDT
Recruiting Phase 1 Interventional

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871
View directory record Official record
Conditions
HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
Interventions
IAM1363
Drug
Lead sponsor
Iambic Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Not applicable Interventional

Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine

NCT00000734
View directory record Official record
Conditions
HIV Infections
Interventions
Sulfamethoxazole-Trimethoprim, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 31, 2026, 2:13 PM EDT
Recruiting Phase 1 Interventional

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

NCT07619599
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Radiation · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 2:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

RAPA-201 Therapy of Solid Tumors

NCT05144698
View directory record Official record
Conditions
Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Malignant Melanoma, Esophageal Squamous Cell Carcinoma
Interventions
RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
Biological · Drug
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 31, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

NCT03481114
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
PET-based, dose-painted, accelerated chemoradiotherapy, Standard chemoradiotherapy
Combination Product
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 31, 2026, 2:13 PM EDT
Recruiting Phase 2 Interventional Results available

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

NCT05242965
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim, Computed Tomography, Biopsy, Biospecimen Collection
Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
2
States / cities
Omaha, Nebraska • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 31, 2026, 2:13 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of Pirfenidone Treatment in HPS-ILD

NCT04193592
View directory record Official record
Conditions
Hermansky Pudlak Syndrome, Interstitial Lung Disease
Interventions
Pirfenidone
Drug
Lead sponsor
Jesse Roman
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 31, 2026, 2:13 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Development of Immune Globulin Treatment for Avian Flu

NCT00383071
View directory record Official record
Conditions
Infectious Diseases, Influenza, Avian Flu
Interventions
H5N1 vaccine, Apheresis
Biological · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 31, 2026, 2:13 PM EDT